INTRODUCTION {#s1}
============

There were an estimated 14.1 million new cancer cases and 8.2 million cancer-related deaths in 2012 worldwide \[[@R1], [@R2]\]. Although recent advances in the diagnosis and treatment of various cancers have improved patient prognosis, most malignancies still impose a heavy burden on society. Cancer is a multifactorial, chronic disease caused by both endogenous (genetic, immune, and endocrine disorders) and exogenous factors (environmental carcinogens and unhealthy behaviors) \[[@R1]\]. Among these etiological factors, gene-environment interactions have been shown to play key roles in cancer development.

The maintenance of genomic integrity is essential for human health. However, DNA damage can occur due to exposure to various chemicals, environmental agents, and ultraviolet radiation. DNA damage can also occur naturally. For example, metabolic processes can generate compounds that damage DNA, which include reactive oxygen and reactive nitrogen species. There are five major DNA damage repair pathways in humans: nucleotide excision repair (NER), base excision repair, double-strand break repair, mismatch repair, and homologous recombination \[[@R3]\]. Failure to properly repair DNA damage can lead to tumorigenesis. The versatile NER pathway is responsible for excising DNA lesions including cross-links, bulky adducts, thymidine dimers, alkylating damage, and oxidative DNA damage \[[@R3]\].

There are at least eight core functional genes in the NER pathway. These include Excision repair cross complementing group 1 (*ERCC1*) and Xeroderma pigmentosum group (*XP*) *A-G*. *XPG*, also known as *ERCC5*, is located on chromosome 13q22-q33 \[[@R4]\]. The *XPG* gene encodes a single-strand specific DNA endonuclease of 1,186 amino acids that cleaves the damaged DNA strand at the 3' end \[[@R5]\]. Defects in the *XPG* gene can impair DNA repair resulting in genomic instability and carcinogenesis \[[@R6]\]. Single nucleotide polymorphisms (SNPs) in the *XPG* gene have been associated with various cancers including colorectal \[[@R7]\], lung \[[@R8], [@R9]\], gastric \[[@R10], [@R11]\], and laryngeal \[[@R12]\]. However, different studies have achieved conflicting results. For example, Duan et al. found that rs2296147 T\>C in *XPG* was associated with an increased risk of gastric cancer \[[@R13]\], but this association was not replicated in other studies \[[@R10], [@R11]\]. The discordances might be attributed to the limited sample sizes of individual studies, different sources of controls, and ethnic variation. In this study, we performed a meta-analysis of the associations between six potentially functional SNPs: rs1047768 T\>C, rs2296147 T\>C, rs2227869 G\>C, rs2094258 C\>T, rs751402 C\>T, and rs873601 G\>A in the *XPG* gene and the risk of cancer.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

A total of 215 articles were identified using the Web of Science, Scopus, and PubMed. An additional 26 potential relevant articles were identified in the CNKI and WanFang databases. After screening the titles and abstracts, 135 studies remained for further full-text review. We excluded 17 meta-analyses and reviews as well as 69 studies that did not assess the SNPs of interest. A detailed assessment was then performed of 49 studies. Two of these studies were removed, one because there was a lack of detailed genotype data and the other because of study population overlap. The final meta-analysis included 47 articles. There were 22 articles with 12,833 cases and 151,86 controls for rs1047768 T\>C \[[@R7]--[@R9], [@R12], [@R14]--[@R31]\], 14 studies with 11,327 cases and 12,684 controls for rs2296147 T\>C \[[@R9]--[@R11], [@R13], [@R18], [@R24], [@R26]--[@R28], [@R32]--[@R37]\], 11 studies with 5,898 cases and 7,448 controls for rs2227869 G\>C \[[@R8], [@R9], [@R14], [@R17], [@R18], [@R20], [@R22], [@R25], [@R38]--[@R40]\], 17 studies with 9,826 cases and 10,552 controls for rs2094258 C\>T \[[@R10], [@R11], [@R18], [@R24], [@R26]--[@R28], [@R34]--[@R37], [@R41]--[@R46]\], 21 studies with 10,369 cases and 11,207 controls for rs751402 C\>T \[[@R10], [@R13], [@R24], [@R26]--[@R29], [@R31], [@R32], [@R36], [@R37], [@R42]--[@R45], [@R47]--[@R52]\], and 14 studies with 10,873 cases and 12,535 controls for rs873601 G\>A \[[@R9]--[@R11], [@R18], [@R24], [@R26]--[@R28], [@R32], [@R34], [@R36], [@R52]--[@R54]\]. A flow chart summarizing the process of relevant study identification is shown in Figure [1](#F1){ref-type="fig"}, and the study characteristics are shown in Table [1](#T1){ref-type="table"}.

![Flow diagram showing the process used to identify eligible studies](oncotarget-08-37263-g001){#F1}

###### Characteristics of the studies included in the meta-analysis

  Author                Year   Country    Ethnicity   Source   Cancer           Case   Control   MAF   HWE    Score                                         
  --------------------- ------ ---------- ----------- -------- ---------------- ------ --------- ----- ------ ------- ------ ------ ------ ------ --------- ----
  **rs1047768 T\>C**                                                                                                                                        
  Shen M                2005   China      Asian       PB       Lung             55     49        14    118    63      36     13     112    0.28   0.037     10
  Zienolddiny S         2006   Norway     Caucasian   PB       Lung             60     119       137   316    109     126    138    373    0.54   \<0.001   11
  Moreno V              2006   Spain      Caucasian   HB       Colorectal       114    184       53    351    105     164    51     320    0.42   0.325     11
  Garcia-Closas M       2006   Spain      Caucasian   HB       Bladder          188    530       385   1103   222     506    366    1094   0.57   0.052     12
  Xie WM                2007   China      Asian       PB       HCC              194    195       38    427    235     196    48     479    0.30   0.451     11
  Abbasi R              2009   Germany    Caucasian   PB       Laryngeal        43     127       78    248    115     320    212    647    0.57   0.762     13
  Hussain SK            2009   China      Asian       PB       Gastric          97     61        12    170    189     168    29     386    0.29   0.173     13
  Ma H                  2012   USA        Caucasian   HB       SCCHN            184    506       369   1059   179     507    379    1065   0.59   0.669     11
  Sakoda LC             2012   USA        Caucasian   PB       Lung             108    378       256   742    245     722    507    1474   0.59   0.656     15
  He J                  2013   China      Asian       HB       Gastric          571    469       85    1125   610     474    112    1196   0.29   0.155     13
  Paszkowska-Szczur K   2013   Poland     Caucasian   PB       Melanoma         128    291       214   633    242     623    465    1330   0.58   0.189     13
  Li X                  2014   China      Asian       HB       Laryngeal        49     101       60    210    46      97     67     210    0.55   0.333     9
  Mirecka A             2014   Poland     Caucasian   HB       Prostate         128    272       221   621    154     368    259    781    0.57   0.260     9
  Li XC                 2014   China      Asian       HB       Gastric          37     95        85    217    29      93     95     217    0.65   0.414     8
  Na N                  2015   China      Asian       HB       Breast           161    140       24    325    171     134    20     325    0.27   0.352     10
  Paszkowska-Szczur K   2015   Poland     Caucasian   HB       Colorectal       104    221       138   463    242     623    465    1330   0.58   0.189     9
  He J                  2016   China      Asian       HB       Neuroblastoma    135    93        20    248    307     198    26     531    0.24   0.409     10
  Hua RX                2016   China      Asian       HB       Colorectal       970    758       173   1901   1023    812    142    1977   0.28   0.266     10
  Hua RX                2016   China      Asian       HB       Gastric          607    445       90    1142   625     461    87     1173   0.27   0.875     11
  Li RJ                 2016   China      Asian       HB       Gastric          57     92        67    216    68      87     61     216    0.48   0.004     7
  Wang MY               2016   China      Asian       HB       Prostate         491    433       80    1004   534     440    81     1055   0.29   0.461     10
  Bai Y                 2016   China      Asian       HB       Gastric          41     98        55    194    32      106    87     225    0.62   0.975     6
  **rs2296147 T\>C**                                                                                                                                        
  Shao MH               2007   China      Asian       HB       Lung             570    304       52    926    590     358    31     979    0.21   0.008     10
  Doherty JA            2011   USA        Mixed       PB       Endometrial      194    356       165   715    199     364    157    720    0.47   0.696     11
  Duan Z                2012   China      Asian       HB       Gastric          257    122       24    403    260     132    11     403    0.19   0.232     11
  He J                  2012   China      Asian       HB       Gastric          700    371       54    1125   742     398    56     1196   0.21   0.779     13
  Ma H                  2012   USA        Caucasian   HB       SCCHN            280    532       244   1056   294     543    228    1065   0.47   0.440     11
  Sakoda LC             2012   USA        Caucasian   PB       Lung             182    385       174   741    407     723    341    1471   0.48   0.565     15
  Zhu ML                2012   China      Asian       HB       ESCC             757    305       53    1115   699     368    50     1117   0.21   0.860     13
  Yang WG               2012   China      Asian       HB       Gastric          208    105       24    337    196     110    41     347    0.28   \<0.001   9
  Yang B                2013   China      Asian       HB       Prostate         37     49        143   229    25      46     167    238    0.80   \<0.001   8
  Na N                  2015   China      Asian       HB       Breast           188    104       33    325    199     98     28     325    0.24   0.003     9
  Sun Z                 2015   China      Asian       HB       NPC              119    177       76    372    111     180    80     371    0.46   0.660     11
  Chen YZ               2016   China      Asian       HB       Gastric          442    217       33    692    475     264    32     771    0.21   0.535     11
  He J                  2016   China      Asian       HB       Neuroblastoma    160    79        9     248    343     170    18     531    0.19   0.583     10
  Hua RX                2016   China      Asian       HB       Colorectal       1169   644       88    1901   1213    692    72     1977   0.21   0.027     9
  Hua RX                2016   China      Asian       HB       Gastric          725    364       53    1142   746     388    39     1173   0.20   0.182     11
  **rs2227869 G\>C**                                                                                                                                        
  Shen M                2005   China      Asian       PB       Lung             103    14        1     118    100     11     0      111    0.05   0.583     11
  Garcia-Closas M       2006   Spain      Caucasian   HB       Bladder          1050   91        2     1143   1046    90     0      1136   0.04   0.164     12
  Huang WY              2006   USA        Caucasian   PB       Colorectal       598    52        1     651    601     60     1      662    0.05   0.694     14
  Hooker S              2008   USA        African     HB       Prostate         234    20        0     254    274     27     0      301    0.05   0.415     7
  Hussain SK            2009   China      Asian       PB       Gastric          174    13        0     187    314     56     3      372    0.08   0.773     13
  Ma H                  2012   USA        Caucasian   HB       SCCHN            987    70        2     1059   974     90     2      1066   0.04   0.958     11
  Sakoda LC             2012   USA        Caucasian   PB       Lung             1      63        680   744    2       110    1362   1474   0.96   0.886     15
  Santos LS             2013   Portugal   Caucasian   HB       Thyroid          99     6         1     106    184     27     1      212    0.02   0.993     8
  Paszkowska-Szczur K   2013   Poland     Caucasian   PB       Melanoma         567    67        2     636    1168    162    2      1332   0.06   0.137     13
  Mirecka A             2014   Poland     Caucasian   HB       Prostate         485    83        3     571    682     99     1      782    0.06   0.181     9
  Paszkowska-Szczur K   2015   Poland     Caucasian   HB       Colorectal       372    55        2     429    1168    162    2      1332   0.06   0.137     9
  **rs2094258 C\>T**                                                                                                                                        
  He J                  2012   China      Asian       HB       Gastric          457    518       150   1125   457     560    179    1196   0.62   0.728     13
  Ma H                  2012   USA        Caucasian   HB       SCCHN            706    295       37    1038   721     291    41     1053   0.82   0.092     11
  Yang WG               2012   China      Asian       HB       Gastric          131    149       57    337    145     166    36     347    0.66   0.252     10
  Zhu ML                2012   China      Asian       HB       ESCC             414    524       177   1115   424     525    168    1117   0.61   0.793     13
  Yang B                2013   China      Asian       HB       Prostate         61     75        93    229    58      75     105    238    0.40   \<0.001   9
  Na N                  2015   China      Asian       HB       Breast           102    157       66    325    131     147    47     325    0.63   0.581     10
  Sun Y                 2015   China      Asian       HB       Laryngeal        140    106       25    271    152     101    18     271    0.75   0.826     11
  Sun Z                 2015   China      Asian       HB       NPC              209    68        95    372    211     66     94     371    0.66   \<0.001   10
  Chen YZ               2016   China      Asian       HB       Gastric          287    304       101   692    291     368    112    771    0.62   0.803     11
  He J                  2016   China      Asian       HB       Neuroblastoma    116    93        39    248    203     254    74     531    0.62   0.701     10
  Hua RX                2016   China      Asian       HB       Colorectal       797    856       248   1901   899     881    197    1977   0.68   0.378     10
  Feng YB               2016   China      Asian       HB       Gastric          15     75        87    177    15      96     127    238    0.26   0.577     6
  Hua RX                2016   China      Asian       HB       Gastric          499    508       135   1142   527     524    122    1173   0.67   0.623     11
  Lu JJ                 2016   China      Asian       HB       Gastric          17     67        100   184    13      72     121    206    0.24   0.605     6
  Ma SH                 2016   China      Asian       HB       Breast           27     136       157   320    15      96     127    238    0.26   0.577     7
  Yang LQ               2016   China      Asian       HB       Gastric          71     74        10    155    121     111    14     246    0.72   0.076     6
  Ying MF               2016   China      Asian       HB       Pancreatic       87     92        16    195    117     115    22     254    0.69   0.400     7
  **rs751402 C\>T**                                                                                                                                         
  Shao MH               2007   China      Asian       HB       Lung             105    429       433   967    110     425    448    983    0.67   0.544     11
  Yoon AJ               2011   Taiwan     Asian       HB       HCC              11     52        33    96     32      137    167    336    0.70   0.614     6
  Duan Z                2012   China      Asian       HB       Gastric          47     181       172   400    29      165    206    400    0.72   0.605     11
  He J                  2012   China      Asian       HB       Gastric          148    491       486   1125   137     499    560    1196   0.68   0.110     13
  Zavras AI             2012   Taiwan     Mixed       HB       OSCC             31     110       98    239    32      137    167    336    0.70   0.614     9
  Meng X                2013   China      Asian       HB       Salivary gland   11     63        59    133    23      55     64     142    0.64   0.065     8
  Na N                  2015   China      Asian       HB       Breast           45     152       128   325    41      147    137    325    0.65   0.872     10
  Sun Z                 2015   China      Asian       HB       NPC              237    118       17    372    235     117    19     371    0.21   0.377     11
  Wang H                2016   China      Asian       HB       Breast           1      10        90    101    11      39     51     101    0.70   0.398     9
  Chen YZ               2016   China      Asian       HB       Gastric          93     313       286   692    89      331    351    771    0.67   0.416     11
  He J                  2016   China      Asian       HB       Neuroblastoma    38     114       96    248    82      241    208    531    0.62   0.380     10
  Hua RX                2016   China      Asian       HB       Colorectal       248    860       792   1900   301     952    724    1977   0.61   0.680     10
  Guo BW                2016   China      Asian       HB       Gastric          22     73        47    142    21      136    117    274    0.68   0.029     5
  Feng YB               2016   China      Asian       HB       Gastric          24     83        70    177    28      107    101    236    0.65   0.967     6
  Hua RX                2016   China      Asian       HB       Gastric          161    555       426   1142   189     551    433    1173   0.60   0.537     11
  Li RJ                 2016   China      Asian       HB       Gastric          22     106       88    216    18      103    95     216    0.68   0.174     8
  Lu JJ                 2016   China      Asian       HB       Gastric          24     91        69    184    22      97     87     206    0.66   0.510     6
  Ma SH                 2016   China      Asian       HB       Breast           43     150       127   320    28      101    107    236    0.67   0.580     7
  Yang LQ               2016   China      Asian       HB       Gastric          33     73        49    155    32      111    103    246    0.64   0.807     6
  Wang MY               2016   China      Asian       HB       Prostate         104    458       442   1004   111     467    477    1055   0.67   0.834     10
  Zhou RM               2016   China      Asian       HB       Gastric          61     196       174   431    46      193    193    432    0.67   0.827     12
  **rs873601 G\>A**                                                                                                                                         
  Shao MH               2007   China      Asian       HB       Lung             260    493       220   973    277     494    217    988    0.47   0.907     11
  He J                  2012   China      Asian       HB       Gastric          274    560       291   1125   327     605    264    1196   0.47   0.616     13
  Ma H                  2012   USA        Caucasian   HB       SCCHN            66     427       565   1058   83      411    572    1066   0.73   0.445     11
  Sakoda LC             2012   USA        Caucasian   PB       Lung             51     299       392   742    107     584    783    1474   0.73   0.894     15
  Yang WG               2012   China      Asian       HB       Gastric          96     163       78    337    91      164    91     346    0.50   0.333     10
  Zhu ML                2012   China      Asian       HB       ESCC             314    566       235   1115   311     565    241    1117   0.47   0.601     13
  Na N                  2015   China      Asian       HB       Breast           99     156       70    325    109     150    66     325    0.43   0.276     10
  Zhao F                2015   China      Asian       HB       Pancreatic       105    111       30    246    118     107    21     246    0.30   0.637     8
  Chen YZ               2016   China      Asian       HB       Gastric          172    333       187   692    205     396    170    771    0.48   0.415     11
  He J                  2016   China      Asian       HB       Neuroblastoma    70     112       66    248    137     270    124    531    0.49   0.686     10
  Wang B                2016   China      Asian       HB       HCC              163    271       104   538    271     408    214    893    0.47   0.014     12
  Hua RX                2016   China      Asian       HB       Colorectal       476    954       471   1901   550     1025   402    1977   0.46   0.057     10
  Hua RX                2016   China      Asian       HB       Gastric          311    557       274   1142   323     598    252    1173   0.47   0.424     11
  Zhou RM               2016   China      Asian       HB       Gastric          115    215       101   431    132     200    100    432    0.46   0.152     12

Abbreviations: HB, hospital-based; PB, population-based; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium; HCC, hepatocellular carcinoma; SCCHN, squamous cell carcinoma of the head and neck; ESCC, esophageal squamous cell carcinoma; OSCC, oral squamous cell carcinoma; NPC, nasopharyngeal carcinoma.

Meta-analysis results {#s2_2}
---------------------

We observed no significant association between rs1047768 T\>Cand overall cancer risk (Table [2](#T2){ref-type="table"}). However, in stratified analysis, rs1047768 T\>C was associated with an increased risk of lung cancer under homozygous \[odds ratio (OR) = 1.32, 95% confidence interval (CI) = 1.06--1.64\], heterozygous (OR = 1.35, 95% CI = 1.10--1.65), dominant (OR = 1.35, 95% CI = 1.12--1.63), and allele contrast (OR = 1.14, 95% CI = 1.02--1.27) models.

###### Associations between the six SNPs in the *XPG* gene and cancer risk

  Variables            No. of studies   No. of cases   No. of controls   Homozygous              Heterozygous   Recessive               Dominant       Allele                                                                                      
  -------------------- ---------------- -------------- ----------------- ----------------------- -------------- ----------------------- -------------- ----------------------- --------- ----------------------- --------- ----------------------- ---------
  **rs1047768 T\>C**   CC vs. TT                       CT vs. TT                                 CC vs. CT/TT                           CC/CT vs. TT                           C vs. T                                                             
  All                  22               12833          15186             1.03 (0.95--1.11)       0.010          1.03 (0.97--1.09)       0.192          1.00 (0.93--1.07)       0.171     1.03 (0.98--1.09)       0.038     1.01 (0.98--1.05)       0.012
  *Ethnicity*                                                                                                                                                                                                                                      
   Caucasian           9                5536           7084              1.03 (0.88--1.21)       0.012          1.04 (0.95--1.14)       0.061          1.00 (0.93--1.07)       0.344     1.04 (0.90--1.20)       0.011     1.01 (0.94--1.10)       0.011
   Asian               13               7297           8102              1.03 (0.92--1.16)       0.081          1.02 (0.96--1.10)       0.493          1.00 (0.90--1.11)       0.116     1.03 (0.96--1.10)       0.304     1.02 (0.97--1.07)       0.105
  *Cancer type*                                                                                                                                                                                                                                    
   Lung                3                1176           1959              **1.32 (1.06--1.64)**   0.175          **1.35 (1.10--1.65)**   0.278          1.08 (0.92--1.26)       0.360     **1.35 (1.12--1.63)**   0.172     **1.14 (1.02--1.27)**   0.059
   Colorectal          3                2715           3627              0.95 (0.63--1.45)       0.006          0.96 (0.86--1.08)       0.480          0.99 (0.70--1.39)       0.012     0.94 (0.78--1.14)       0.133     0.99 (0.91--1.07)       0.020
   Gastric             6                3064           3413              0.88 (0.74--1.05)       0.118          0.98 (0.88--1.09)       0.263          0.88 (0.74--1.05)       0.279     0.97 (0.87--1.07)       0.127     0.93 (0.82--1.04)       0.073
   Others              10               5878           7517              1.04 (0.93--1.15)       0.507          1.05 (0.96--1.14)       0.670          1.01 (0.93--1.10)       0.725     1.05 (0.97--1.14)       0.628     1.03 (0.98--1.08)       0.659
  **rs2296147 T\>C**   CC vs. TT                       CT vs. TT                                 CC vs. CT/TT                           CC/CT vs. TT                           C vs. T                                                             
  All                  15               11327          12684             1.10 (1.00--1.12)       0.068          0.95 (0.90--1.01)       0.480          1.08 (0.99--1.18)       0.057     0.97 (0.92--1.03)       0.297     1.00 (0.96--1.04)       0.118
   Gastric             5                3699           3890              1.11 (0.76--1.60)       0.026          0.95 (0.86--1.04)       0.945          1.13 (0.78--1.63)       0.025     0.96 (0.88--1.06)       0.697     0.99 (0.91--1.07)       0.197
  **rs2227869 G\>C**   CC vs. GG                       GC vs. GG                                 CC vs. GC/GG                           GC/CC vs. GG                           C vs. G                                                             
  All                  11               5898           7448              1.67 (0.82--3.41)       0.924          0.90 (0.80--1.02)       0.153          0.98 (0.73--1.32)       0.699     0.92 (0.81--1.03)       0.108     0.93 (0.83--1.04)       0.079
   PB                  5                2336           3951              1.08 (0.37--3.10)       0.793          **0.80 (0.65--0.99)**   0.239          0.89 (0.65--1.21)       0.766     0.81 (0.66--1.00)       0.170     **0.84 (0.71--0.99)**   0.115
   HB                  6                3562           4829              2.46 (0.91--6.67)       0.852          0.96 (0.82--1.11)       0.198          2.48 (0.91--6.74)       0.865     0.98 (0.84--1.13)       0.190     1.00 (0.87--1.15)       0.202
  **rs2094258 C\>T**   TT vs. CC                       CT vs. CC                                 TT vs. CT/CC                           CT/TT vs. CC                           T vs. C                                                             
  All                  17               9826           10552             1.09 (1.00--1.19)       0.025          1.00 (0.94--1.07)       0.314          1.07 (0.99--1.16)       0.089     1.02 (0.97--1.09)       0.081     1.03 (0.99--1.08)       0.015
   Gastric             7                3812           4177              0.99 (0.86--1.15)       0.083          0.95 (0.86--1.05)       0.734          1.01 (0.89--1.14)       0.119     0.96 (0.88--1.06)       0.409     0.98 (0.92--1.05)       0.133
  **rs751402 C\>T**    TT vs. CC                       CT vs. CC                                 TT vs. CT/CC                           CT/TT vs. CC                           T vs. C                                                             
  All                  21               10369          11207             1.18 (1.00--1.39)       \<0.001        1.10 (0.99--1.23)       0.082          1.02 (0.94--1.10)       0.006     1.11 (0.98--1.25)       \<0.001   1.08 (0.98--1.18)       \<0.001
   Gastric             10               4664           5150              **1.38 (1.12--1.70)**   0.020          **1.14 (1.05--1.24)**   0.936          **1.27 (1.06--1.51)**   0.053     **1.17 (1.08--1.26)**   0.437     **1.17(1.07--1.27)**    0.043
  **rs873601 G\>A**    AA vs. GG                       GA vs. GG                                 AA vs. GA/GG                           GA/AA vs. GG                           A vs. G                                                             
  All                  14               10873          12535             **1.14 (1.06--1.24)**   0.193          1.06 (0.99--1.13)       0.904          1.08 (0.99--1.17)       0.035     **1.08 (1.02--1.15)**   0.841     **1.06 (1.02--1.10)**   0.234
   Gastric             5                3727           3918              **1.18 (1.04--1.34)**   0.333          1.04 (0.93--1.16)       0.663          **1.16 (1.04--1.28)**   0.263     1.08 (0.98--1.20)       0.578     **1.09 (1.02--1.16)**   0.336

No significant association was observed between rs2296147 T\>C and overall cancer risk. Similarly, there was no significant association between rs2227869 G\>C and overall cancer risk. However, a significant association was identified in population-based studies when the data were stratified based on the source of the controls under heterozygous (OR = 0.80, 95% CI = 0.65--0.99) and allele contrast (OR = 0.84, 95% CI = 0.71--0.99) models. We observed an association between rs2094258 C\>T and overall cancer risk under the homozygous model (OR = 1.09, 95% CI = 1.00--1.19), which approached borderline statistical significance. Another borderline significant association was observed between rs751402 C\>T and overall cancer risk under the homozygous model (OR = 1.18, 95% CI = 1.00--1.39). In the stratified analysis, a significant association was observed for gastric cancer under homozygous (OR = 1.38, 95% CI = 1.12--1.70), heterozygous (OR = 1.14, 95% CI = 1.05--1.24), recessive (OR = 1.27, 95% CI = 1.06--1.51), dominant (OR = 1.17, 95% CI = 1.08--1.26), and allele contrast (OR = 1.17, 95% CI = 1.07--1.27) models.

A significant association was observed between rs873601 G\>A and overall cancer risk under homozygous (OR = 1.14, 95% CI = 1.06--1.24), dominant (OR = 1.08, 95% CI = 1.02--1.15), and allele contrast (OR = 1.06, 95% CI = 1.02-1.10) models (Figure [2](#F2){ref-type="fig"}). The association with gastric cancer remained statistically significant under homozygous (OR = 1.18, 95% CI = 1.04--1.34), recessive (OR = 1.16, 95% CI = 1.04--1.28), and allele contrast (OR = 1.09, 95% CI = 1.02--1.16) models.

![Forest plot of overall cancer risk associated with rs873601 G\>A in the *XPG* gene under an allele contrast model\
For each study, estimated ORs and 95% CIs are plotted with a box and horizontal line, respectively. (◇, pooled ORs and associated 95% CIs).](oncotarget-08-37263-g002){#F2}

Heterogeneity and sensitivity analysis {#s2_3}
--------------------------------------

Study heterogeneity was observed for the association between rs1047768 T\>C and overall cancer risk under homozygous, dominant, and allele contrast models (*P* = 0.010, *P* = 0.038, and *P* = 0.012, respectively); rs2094258 C\>T under homozygous and allele contrast models (*P* = 0.025 and *P* = 0.015, respectively); rs751402 C\>T under homozygous, recessive, dominant, and allele contrast models (*P* \< 0.001, *P* = 0.006, *P* \< 0.001, *P* \< 0.001, respectively); and rs873601 G\>A under a recessive model (*P* = 0.035). These data indicated that the removal of any individual study from the analysis did not qualitatively change the pooled ORs (data not shown).

Publication bias {#s2_4}
----------------

The Begg\'s funnel plots of the associations between the SNPs in the *XPG* gene and cancer risk were basically symmetrical (Figure [3](#F3){ref-type="fig"}). Egger\'s tests indicated there was no publication bias for rs1047768 T\>C under homozygous (*P* = 0.107), heterozygous (*P* = 0.190), recessive (*P* = 0.325), dominant (*P* = 0.137), and allele contrast (*P* = 0.301) models; rs2296147 T\>C under homozygous (*P* = 0.789), heterozygous (*P* = 0.925), recessive (*P* = 0.577), dominant (*P* = 0.464), and allele contrast (*P* = 0.129) models; rs2227869 G\>C under homozygous (*P* = 0.708), heterozygous (*P* = 0.289), recessive (*P* = 0.042), dominant (*P* = 0.297), and allele contrast (*P* = 0.197) models; rs2094258 C\>T under homozygous (*P* = 0.387), heterozygous (*P* = 0.350), recessive (*P* = 0.844), dominant (*P* = 0.276), and allele contrast (*P* = 0.351) models; rs751402 C\>T under homozygous (*P* = 0.107), heterozygous (*P* = 0.336), recessive (*P* = 0.137), dominant (*P* = 0.325), and allele contrast (*P* = 0.301) models; and rs873601 G\>A under homozygous (*P* = 0.395), heterozygous (*P* = 0.656), recessive (*P* = 0.645), dominant (*P* = 0.811), and allele contrast (*P* = 0.346) models (Table [3](#T3){ref-type="table"}).

![Funnel plot of the association between rs873601 G\>A in the *XPG* gene and overall cancer risk under an allele contrast model\
Each point represents an individual study that reported the indicated association.](oncotarget-08-37263-g003){#F3}

###### Publication bias among studies that evaluated the associations between the six SNPs in the *XPG* gene and cancer susceptibility

  Polymorphism   No. of studies   Egger\'s test *P* values                           
  -------------- ---------------- -------------------------- ------- ------- ------- -------
  rs1047768      22               0.107                      0.190   0.325   0.137   0.301
  rs2296147      15               0.789                      0.925   0.577   0.464   0.129
  rs2227869      11               0.708                      0.289   0.042   0.297   0.197
  rs2094258      17               0.387                      0.350   0.844   0.276   0.351
  rs751402       21               0.107                      0.336   0.137   0.325   0.301
  rs873601       14               0.395                      0.656   0.645   0.811   0.346

False-positive *report probability (FPRP) analysis and* trial sequential analysis (TSA) {#s2_5}
---------------------------------------------------------------------------------------

All significant findings remained significant at a prior probability of 0.1, with all the FPRP values less than 0.20 with the exception of the population-designed studies of rs2227869 G\>C (Table [4](#T4){ref-type="table"}). TSA indicated that the cumulative z-curve crossed the trial sequential monitoring boundary, suggesting that the sample size was sufficient and that no further analysis was required to confirm the results (Figure [4](#F4){ref-type="fig"}).

###### False-positive report probability values for significant results

  Genotype                                    Crude OR (95% CI)   *P* ^a^   Statistical power ^b^   Prior probability                                       
  ------------------------------------------- ------------------- --------- ----------------------- ------------------- ----------- ----------- ----------- -------
  rs1047768 T\>C (lung cancer)                                                                                                                              
   CC vs. TT                                  1.32 (1.06--1.64)   0.012     0.998                   **0.035**           **0.097**   0.542       0.923       0.992
   CT vs. TT                                  1.35 (1.10--1.65)   0.004     0.995                   **0.011**           **0.033**   0.273       0.791       0.974
   CC/CT vs. TT                               1.35 (1.12--1.63)   0.002     0.859                   **0.006**           **0.019**   **0.177**   0.685       0.956
  C vs. T                                     1.14 (1.02--1.27)   0.017     1.000                   **0.048**           **0.130**   0.622       0.943       0.994
  rs2227869 G\>C (population-based studies)                                                                                                                 
   GC vs. GG                                  0.80 (0.65--0.99)   0.041     0.987                   **0.111**           0.272       0.805       0.976       0.998
   C vs. G                                    0.84 (0.71--0.99)   0.041     1.000                   **0.110**           0.271       0.803       0.976       0.998
  rs751402 C\>T (gastric cancer)                                                                                                                            
   TT vs. CC                                  1.38 (1.12--1.70)   0.002     1.000                   **0.007**           **0.019**   **0.179**   0.687       0.956
   CT vs. CC                                  1.14 (1.05--1.24)   0.003     1.000                   **0.008**           **0.024**   0.213       0.732       0.965
   TT vs. CT/CC                               1.27 (1.06--1.51)   0.010     1.000                   **0.030**           **0.085**   0.506       0.912       0.990
   CT/TT vs. CC                               1.17 (1.08--1.26)   \<0.001   1.000                   **0.001**           **0.002**   **0.019**   **0.161**   0.658
   T vs. C                                    1.17 (1.07--1.27)   0.001     1.000                   **0.002**           **0.006**   **0.063**   0.404       0.871
  rs873601 G\>A (overall)                                                                                                                                   
   AA vs. GG                                  1.14 (1.06--1.24)   0.001     1.000                   **0.002**           **0.006**   **0.061**   0.394       0.867
   GA/AA vs. GG                               1.08 (1.02--1.15)   0.012     1.000                   **0.036**           **0.101**   0.552       0.926       0.992
   A vs. G                                    1.06 (1.02--1.10)   0.002     1.000                   **0.006**           **0.016**   **0.155**   0.650       0.949
  rs873601 G\>A (gastric cancer)                                                                                                                            
   AA vs. GG                                  1.18 (1.04--1.34)   0.009     1.000                   **0.027**           **0.078**   0.482       0.904       0.989
   AA vs. GA/GG                               1.16 (1.04--1.28)   0.008     1.000                   **0.022**           **0.064**   0.431       0.884       0.987
   A vs. G                                    1.09 (1.02--1.16)   0.011     1.000                   **0.031**           **0.089**   0.517       0.915       0.991

^a^Chi-square tests were used to assess the genotype frequency distributions.

^b^Statistical power was calculated using the number of observations in the subgroup and the *P* values in this table.

![TSA of rs873601 G\>A in the *XPG* gene and overall cancer risk under an allele contrast model](oncotarget-08-37263-g004){#F4}

DISCUSSION {#s3}
==========

The NER pathway is critical for the repair of bulky DNA lesions resulting from exposure to chemical carcinogens as well as ionizing radiation in order to maintain genomic integrity and prevent carcinogenesis \[[@R55]\]. Because the *XPG* gene is an indispensable component of the NER pathway, SNPs in *XPG* may alter the expression or function of XPG thereby modifying the risk of cancer. Most previous meta-analyses of the association between SNPs in *XPG* and cancer risk have focused on rs17655 G\>C \[[@R56]--[@R59]\]. However, recent studies have shown that other SNPs in *XPG* may also be associated with cancer risk. For example, Chen et al. found that rs873601 G\>A was associated with an increased risk of gastric cancer in a Chinese Han population \[[@R36]\]. Wang et al. found that rs751402 C\>T was protective against breast cancer in Chinese Han women \[[@R47]\]. Additionally, the T allele of rs2296147 was associated with an increased risk of prostate cancer \[[@R35]\]. However, the results of previous studies have been inconsistent, possibly due to variations in the study populations and limited sample sizes. We therefore performed a meta-analysis of 47 studies to comprehensively evaluate the associations between six SNPs in *XPG*: rs1047768 T\>C, rs2296147 T\>C, rs2227869 G\>C, rs2094258 C\>T, rs751402 C\>T, and rs873601 G\>A and cancer risk.

The rs873601 G\>A polymorphism is located in a miRNA binding site in the *XPG* gene. Thus, it may alter *XPG* expression by modulating the miRNA-mRNA interaction, which could play a role in carcinogenesis \[[@R10]\]. We demonstrated that rs873601 G\>A was significantly associated with overall cancer risk. Individuals with the AA genotype of rs873601 had a 1.14-fold higher risk of cancer compared to individuals with the GG genotype. Similar results were obtained for gastric cancer. The A allele of rs873601 was previously shown to result in reduced mRNA expression of *XPG* in both adjacent normal gastric cancer tissue and normal cell lines in a recessive manner \[[@R10]\]. These findings provide insight into the molecular mechanisms by which the AA genotype of rs873601 may increase the risk of gastric cancer.

The rs751402 C\>T polymorphism is located in the E2F1/YY1 binding and response site in the proximal promoter region of *XPG* \[[@R60]\]. This variant might reduce the DNA repair capacity of XPG by disrupting the DNA binding motifs and altering transcription factor affinities \[[@R47]\]. In our study, rs751402 C\>T was significantly associated with overall cancer risk. The TT genotype of rs751402 was associated with an 18% increase in cancer risk compared to the CC genotype. Moreover, a significant association was observed between rs751402 C\>T and gastric cancer risk under all genetic models. The rs751402 C\>T polymorphism is likely to influence cancer risk by regulating *XPG* expression, but its effect on XPG function is not yet clear \[[@R47]\].

The rs2094258 C\>T polymorphism is located in a transcription factor binding site in the 5' region of the *XPG* gene. We found that the association between rs2094258 C\>T and overall cancer risk was borderline significant. Individuals with the TT genotype of rs2094258 had a 9% higher risk of cancer compared to those with the CC genotype. However, the association was not significant in gastric cancer, indicating that it may not impact gastric cancer risk. Significant associations were observed among some subgroups for all other selected SNPs. We found that the C allele of rs1047768 may increase the risk of lung cancer. Moreover, the C allele of rs2227869 significantly reduced cancer risk in population-based studies. No statistically significant association was observed between rs2296147 T\>C and overall cancer risk.

Although we found significant associations between SNPs in the *XPG* gene and cancer risk, our study had several limitations. First, although Egger\'s tests showed no obvious publication bias, some bias was unavoidable since only studies published in English and Chinese were included in our meta-analysis. Second, we observed significant heterogeneity in some of our analyses, which is a common drawback of a meta-analysis. Third, due to a lack of sufficient individual data, we were unable to perform multivariate analysis with adjustment for potential confounding factors such as tobacco use, alcohol consumption, and other carcinogenic factors.

Our study is the first meta-analysis of the association between the six selected SNPs in *XPG* gene and cancer risk. The results indicate that the AA genotype of rs873601 increases overall cancer risk. Additionally, rs751402 C\>T and rs873601 G\>A were associated with gastric cancer risk. Finally, rs1047768 T\>C was found to confer susceptibility to lung cancer. Further epidemiological investigations with larger sample sizes are warranted to validate our findings. Functional studies are also required to elucidate the mechanisms by which these SNPs modify cancer risk.

MATERIALS AND METHODS {#s4}
=====================

Study identification {#s4_1}
--------------------

We searched multiple databases including PubMed, Scopus, Web of Science, CNKI, and the WanFang database using combinations of keywords such as "*XPG*", "polymorphism", and "cancer" as well as synonyms "Xeroderma pigmentosum group G, ERCC5 or Excision repair cross complementing group 5", "variant or variation", and "tumor, neoplasm, or carcinoma". Human studies published before December 20, 2016 in either English or Chinese were included. The reference lists in eligible studies and review articles were examined in order to identify additional relevant studies. In cases of study population overlap, the study with the largest sample size was selected.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

All studies included in this analysis were required to meet the following criteria: (1) study of the associations between any of the six potentially functional SNPs: rs1047768 T\>C, rs2296147 T\>C, rs2227869 G\>C, rs2094258 C\>T, rs751402 C\>T, and rs873601 G\>A in the *XPG* gene and cancer risk; (2) case-control study; and (3) sufficient genotype data available to calculate ORs and 95% CIs. The exclusion criteria were: (1) studies conducted in the same or overlapping population and (2) review article or conference report.

Data extraction {#s4_3}
---------------

Key information was independently extracted from eligible studies by two investigators and included the following items: the first author, year of publication, type of cancer, country, ethnicity, control source, number of cases and controls, the quantity of each genotype in cases and controls, minor allele frequency (MAF), and the Hardy-Weinberg equilibrium (HWE) test *P* value for the control subjects. Disagreements regarding these items were resolved through discussion.

Statistical analysis {#s4_4}
--------------------

Chi-square tests were used to test deviation from HWE in the study control groups. Genetic associations between the six selected SNPs in the *XPG* gene and cancer risk were assessed using the crude ORs and corresponding 95% CIs under homozygous, heterozygous, recessive, dominant, and allele contrast models. Heterogeneity between studies was assessed using the Q and *I*^2^ values. A random effects model was adopted to calculate the pooled OR and 95% CI in the case of *P*^het^ \< 0.1 or I^2^ \> 50%. Otherwise, a fixed effects model was applied. Stratified analyses were conducted by ethnicity (Asians and Caucasians), source of control \[population-based (PB) or hospital-based (HB)\], and cancer type.

Sensitivity analyses were performed to assess the influence of the individual studies on the pooled OR by sequentially removing one study at a time and recalculating the pooled OR. Egger\'s tests were used to evaluate publication bias. FPRP analysis \[[@R61], [@R62]\] and TSA were performed as described previously \[[@R63]\]. All statistical analyses were performed using the STATA 12.0 software (Stata Corporation, College Station, TX, USA). All statistics were two-sided. *P* values \< 0.05 were considered statistically significant.
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